KEGG   DRUG: ReteplaseHelp
Entry
D05721                      Drug                                   

Name
Reteplase (USAN/INN);
Retevase (TN)
Formula
C1736H2653N499O522S22
Exact mass
39546.0247
Mol weight
39571.1001
Sequence
SYQGNSDCYF GNGSAYRGTH SLTESGASCL PWNSMILIGK VYTAQNPSAQ ALGLGKHNYC
RNPDGDAKPW CHVLKNRRLT WEYCDVPSCS TCGLRQYSQP QFRIKGGLFA DIASHPWQAA
IFAKHRRSPG ERFLCGGILI SSCWILSAAH CFQERFPPHH LTVILGRTYR VVPGEEEQKF
EVEKYIVHKE FDDDTYDNDI ALLQLKSDSS RCAQESSVVR TVCLPPADLQ LPDWTECELS
GYGKHEALSP FYSERLKEAH VRLYPSSRCT SQHLLNRTVT DNMLCAGDTR SGGPQANLHD
ACQGDSGGPL VCLNDGRMTL VGIISWGLGC GQKDVPGVYT KVTNYLDWIR DNMRP
(Disulfide bridge: 8-89; 29-71; 60-84; 92-223; 135-151; 143-212; 273-312; 269-285; 302-330)
  Type
Peptide
Class
Cardiovascular agent
 DG01950  Antithrombotic agent
  DG01707  Fibrinolytic
   DG01664  Tissue plasminogen activator (t-PA)
 DG01707  Fibrinolytic
  DG01664  Tissue plasminogen activator (t-PA)
Remark
ATC code: 
Efficacy
Thrombolytic, Tissue plasminogen activator (t-PA)
Comment
tissue plasminogen activator (t-PA) [HSA:5327] [KO:K01343] [EC:3.4.21.68]
Myocardial infarction therapy
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AD Enzymes
     B01AD07 Reteplase
      D05721  Reteplase (USAN/INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05721
BRITE hierarchy
Other DBs
CAS: 
133652-38-7
PubChem: 
DrugBank: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system